bezafibrate has been researched along with Diabetic Angiopathies in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boden, WE | 1 |
| Malcolm, J; Meggison, H; Sigal, R | 1 |
| Fukushima, H; Jinnouchi, H; Koga, H; Kugiyama, K; Ogawa, H; Sakamoto, T; Sugiyama, S; Watanabe, K; Yoshimura, M | 1 |
| Patel, J | 1 |
| Arnaout, A; Malcolm, J; Sigal, R | 1 |
| Dhanjil, S; Diamond, JR; Elkeles, RS; Feher, MD; Mahmood, S; Mather, H; Nicolaides, AN; Poulter, C; Richmond, W; Sharp, P | 1 |
| Attia, N; Autran, D; Dedecjus, M; Durlach, V; Girard-Globa, A | 1 |
| Robinson, S; Valabhji, J | 1 |
| Elkeles, RS; Richmond, W; Seviour, PW; Teal, TK | 1 |
| Benker, G; Cissewski, K; Kienast, K; Reinwein, D; Windeck, R | 1 |
4 review(s) available for bezafibrate and Diabetic Angiopathies
| Article | Year |
|---|---|
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Metabolic Syndrome; Practice Guidelines as Topic | 2003 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Coronary Artery Bypass; Diabetic Angiopathies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Platelet Glycoprotein GPIIb-IIIa Complex; Smoking Cessation | 2004 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin | 2006 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopidogrel; Diabetic Angiopathies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Smoking Cessation; Ticlopidine | 2006 |
2 trial(s) available for bezafibrate and Diabetic Angiopathies
| Article | Year |
|---|---|
Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
Topics: Adult; Aged; Bezafibrate; Carotid Arteries; Cholesterol; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Electrocardiography; Exercise Test; Female; Femoral Artery; Fibrinogen; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Placebos; Time Factors; Triglycerides; Ultrasonography | 1998 |
Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention.
Topics: Aged; Alkaline Phosphatase; Apoproteins; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Lipoproteins, HDL; Male; Middle Aged; Prospective Studies; Triglycerides | 1988 |
4 other study(ies) available for bezafibrate and Diabetic Angiopathies
| Article | Year |
|---|---|
Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease.
Topics: Angina Pectoris; Bezafibrate; Blood Platelets; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Risk Factors | 2006 |
Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment.
Topics: Bezafibrate; Biological Transport; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypolipidemic Agents; Male; Middle Aged; Postprandial Period | 2000 |
Diabetes and lipids - a conundrum.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Electrocardiography; Humans; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Triglycerides | 2001 |
[Bezafibrate-induced myoglobinuric kidney failure in a 54-year-old patient with diabetes mellitus type IIa].
Topics: Acute Kidney Injury; Bezafibrate; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Humans; Middle Aged; Myoglobinuria; Rhabdomyolysis | 1988 |